Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion (original) (raw)

2006, New England Journal of Medicine

Myelodysplastic syndrome (MDS) associated with chromosome 5q31 deletion is characterized by severe anemia that is often refractory to cytokine therapy. We investigated whether lenalidomide (CC5013; Revlimid™) would restore erythropoiesis in red blood cell (RBC) transfusion-dependent patients and suppress the abnormal clone.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact